The objective of the study was to determine the prevalence of mastitis among primiparous heifers at calving and at drying off in 11 Waikato dairy herds during the 1993-94 dairy production season. Duplicate quarter milk samples were collected aseptically from 458 heifers within 5 days after calving for bacteriological analysis. Mastitis was diagnosed in at least one quarter in 35.6% of these heifers. Coagulase-negative staphylococci were isolated from 21.8% of the heifers. The prevalence of coagulase-negative staphylococci varied between herds from 4.3% to 44.8%. Environmental streptococci caused mastitis in 12.2% of heifers, ranging from 5.6% to 24.1% between herds. Streptococcus uberus was the pathogen identified most frequently at calving and accounted for more than 90% of the streptococcal isolates. Staphylococcus aureus and coliforms were isolated from less than 1% of samples. Clinical mastitis was observed in 8.1% of heifers at calving; environmental streptococci were isolated from 67.6% of these clinical clinical cases. Only 2.8% of heifers developed clinical mastitis during lactation and environmental streptococci were isolated from 38.5% of these cases. The prevalence of mastitis among 428 of the heifers at drying off was 64.7%; a 1.8 fold increase during lactation. Corynebactetium bovis was isolated from 43% of heifers at drying off even though it was not isolated from any heifers at calving. During the season, the prevalence of Staphylococcus aureus mastitis increased to 2.8% while mastitis caused by environmental streptococci declined to 2.8%. The prevalence of environmental mastitis pathogens decreased during lactation while contagious pathogens increased in each of the 11 herds. Ineffective post-milking teat sanitation probably contributed to the increase in mastitis caused by contagious pathogens. Specific factors were not determined that affected the variation in prevalence between herds.
Two dry-cow therapy products were evaluated in seven factory-supply dairy herds in the Waikato area. A product containing neomycin sulphate and the benzathine salt of penicillin (Neopen D.C. White; Smith-Biolab) was used in five herds, and one containing benzathine cloxacillin (Orbenin, Beecham) was used in two herds. Non-treated control cows were included in each herd. Both products were effective in eliminating intramammary infections with Staphylococcus aureus, Streptococcus uberis, and Streptococcus agalactiae. Efficacy of dry-cow therapy against S. aureus was 83.8% and 85.2% respectively. Spontaneous cure rate among controls was 30.8% for S. aureus during the dry period. Spontaneous cure rate for Str. uberis was 50%, while dry-cow therapy eliminated 100% and 77.8%, respectively, for the two products. Dry-cow therapy with either product eliminated more than 90% of Str. agalactiae infections while spontaneous cure rate was only 28.6%. These results further support the effectiveness of dry-cow therapy in reducing the level of subclinical mastitis in dairy herds by shortening the duration of intramammary infections.
Four dry-cow treatment regimens were evaluated against Staphylococcus aureus intramammary infections: 1) high persistency product at drying off and low persistency product 1 to 3 days prepartum; 2) high persistency product at drying off; 3) low persistency product 1 to 3 days prepartum; 4) untreated controls. Treatment 1 was no more efficacious (64.4%) than Treatment 2 (61.3%). Both treatments were significantly different from spontaneous recovery observed in Treatment 4 (41.2%), but not significantly different from Treatment 3 (46.9%). Dry-cow therapy reduced new S. aureus intramammary infections during the dry period by half. Prepartum treatment eliminated more than 90% of new Streptococcus uberis infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.